[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"allergic-rhinitis-due-to-house-dust-mite\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:allergic-rhinitis-due-to-house-dust-mite":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,85],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100627726","the-efficacy-of-specific-immunotherapy-guided-by-component-resolved-diagnosis-for-dust-mite-allergens-in-chinese-pediatric-patients-with-rhinitis-andor-asthma-100627726",false,"NCT07452380","The Efficacy of Specific Immunotherapy Guided by Component-Resolved Diagnosis for Dust Mite Allergens in Chinese Pediatric Patients With Rhinitis and\u002For Asthma","A Multicenter Registry Study Examining the Efficacy of Specific Immunotherapy Guided by Component-Resolved Diagnosis for Dust Mite Allergens in Chinese Pediatric Patients With Rhinitis and\u002For Asthma（EXPLORER STUDY）","Inclusion Criteria:\n\n-(1) Age: 5 years ≤ age \\\u003C 18 years; (2) 1) Allergic rhinitis caused by Dermatophagoides pteronyssinus and\u002For Dermatophagoides farinae; 2) Or serum specific IgE ≥ 0.70 (kU\u002FL) (for D. pteronyssinus and\u002For D. farinae); (3) Children meeting criteria (2) must undergo allergen component testing; (4) If accompanied by bronchial asthma, asthma must be diagnosed according to the Guidelines for the Diagnosis and Prevention of Childhood Bronchial Asthma (2025 edition) and the patient's asthma symptoms must be confirmed as well-controlled.\n\n(5) Receiving treatment with dual-mite (Dermatophagoides pteronyssinus and farinae) subcutaneous immunotherapy (SCIT).\n\nExclusion Criteria:\n\n* (1) Participants and\u002For their parents\u002Flegal guardians are judged by the investigator to be unable to fully understand the study requirements, or to adhere to long-term treatment and identify adverse reactions (including but not limited to conditions such as cognitive impairment or mental illness); (2) Children with severe or uncontrolled asthma (FEV1 \\\u003C 70% of predicted value) or with irreversible airflow obstruction; (3) Children using beta-blockers or angiotensin-converting enzyme inhibitors (ACEI); (4) Children with severe autoimmune diseases or immunodeficiencies, including AIDS, inflammatory bowel disease, etc., as well as those currently using immunosuppressants; (5) Children with severe cardiovascular diseases or malignant tumors; (6) Children with incomplete clinical data.","ALL","5 Years","18 Years",{"count":20,"type":21},1000,"ESTIMATED","3 Years","OBSERVATIONAL","This study is a Study to Understand How to Better Match Allergy Shots to a Child's Unique Mite Allergy Profile\n\n1. Why is this study being done? For many children, tiny house dust mites are a major cause of persistent allergies, leading to uncomfortable symptoms like a stuffy nose, sneezing, and even asthma. A common long-term treatment is allergy shots, also known as allergen immunotherapy (AIT). These shots work like a vaccine, slowly training the body's immune system to stop overreacting to mites. However, not every child responds to this treatment in the same way. The investigators now know that children can be allergic to different parts of the dust mite. While most treatments focus on the most common parts (called \"major allergens\"), some children are allergic to other, less common parts (called \"intermediate or minor allergens\").\n\n   The EXPLORER study wants to find out if a child's unique allergy profile-meaning which specific mite proteins they are allergic to-affects how well they respond to allergy shots. Our goal is to move away from a \"one-size-fits-all\" approach and toward more personalized care for children with dust mite allergies.\n2. Who is this study for? The investigators are looking for children and teenagers (ages 5 to 18) in China who have a confirmed dust mite allergy and are planning to start allergy shots.\n3. What will happen during the study? This is an \"observational\" study, which means the investigators will simply observe and track the progress of children who are already receiving a standard, approved allergy shot treatment as part of their regular medical care. The investigators won't be testing a new drug.\n\n   Here's what participation involves:\n\n   A Detailed Allergy Test: At the beginning, participants will have a special blood test. This test will look for allergies to nine different specific parts of the dust mite, giving us a very detailed map of their allergy.\n\n   Grouping: Based on the results of this test, participants will be placed into different groups according to their specific allergy patterns.\n\n   Tracking Progress: The investigators will follow their treatment journey for three years. The investigators will collect information at regular check-ups (at 0, 3, 6, 12, 24, and 36 months) on:\n\n   How well their symptoms are controlled. How much allergy medication they need. Their overall quality of life. Any side effects from the shots. Annual Blood Tests: Once a year, the investigators will repeat the detailed blood test to see how their immune system is changing in response to the treatment.\n4. What do the investigators hope to learn? The investigators have a main theory, or hypothesis: Children who are allergic to many different parts of the dust mite (including the minor ones) will show greater improvement from the allergy shots, compared to children who are only allergic to the most common parts.\n\n   By studying a large group of 1,000 children, the investigators hope to provide clear evidence that can help doctors choose the right treatment for the right child. This will help fill a current gap in medical guidelines and bring us closer to truly personalized treatment for pediatric allergies.\n5. Why is this study important? This is the first large-scale study of its kind in a real-world setting. The results could change how doctors diagnose and treat dust mite allergies in children. Instead of just knowing a child is allergic to mites, the investigators will be able to see the full picture of how they are allergic. This knowledge will help ensure that every child receives the treatment that gives them the best chance for long-term relief.",[26],"Allergic Rhinitis Due to House Dust Mite",[28,29,30,31,32,33],"House dust mite","allergic rhinitis","Component-Resolved Diagnosis","Allergen Immunotherapy","subcutaneous immunotherapy","asthma","RECRUITING","2026-03-05",{"date":37,"type":38},"2026-03-09","ACTUAL",{"date":40,"type":38},"2025-11-01",{"date":42,"type":21},"2028-11-01",{"name":44,"class":45},"The Children's Hospital of Zhejiang University School of Medicine","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":57,"conditions":58,"keywords":63,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":4},"100600357","noninterventional-study-on-tolerability-and-safety-of-one-strength-updosing-with-novo-helisen-depot-house-dust-mites-100600357","NCT07096440","Noninterventional Study on Tolerability and Safety of One Strength Updosing With Novo-Helisen Depot House Dust Mites","NOVo-Helisen Depot HoUSe Dust Mites - A Prospective, Multicenter, Noninterventional Clinical Study on the Tolerability and Safety of Short One Strength UP-dosing in Children, Adolescents, and Adults in Daily Practice","NOVUS-UP","Inclusion Criteria:\n\n* Written informed consent from the patient. For patients under the age of 18, the consent of both parents\u002Flegal guardians is also required.\n* Patients who are eligible for treatment with the One Strength dose escalation scheme of NHD (D.p.\u002FD.f.) according to the specifications in the SmPC. These include children (5 to \\\u003C12 years), adolescents (≥12 to \\\u003C18 years) and adults (≥18 years) with allergic (IgE-mediated) diseases, such as allergic rhinitis, allergic conjunctivitis, allergic bronchial asthma (see section 4 of the current SmPC)\n* The treatment decision must precede the decision to participate in the study and must be independent.\n\nExclusion Criteria:\n\n* Any contraindication according to section 4.3 of the current SmPC for NHD (D.p.\u002FD.f.) for the One Strength dose escalation scheme.",{"count":56,"type":21},105,"The goal of this non-interventional study is to investigate the safety and tolerability of a new simplified up-dosing schedule for Novo-Helisen Depot.\n\nNovo-Helisen Depot is an approved allergen immunotherapy used to treat allergies to house dust mites. For allergen immunotherapy, it is important that the allergen dose is gradually increased, a process known as up-dosing to induce immune tolerance to the allergen. The recently approved One Strength up-dosing scheme for Novo-Helisen Depot allows up-dosing with 6 injections instead of the previously required 14 injections.\n\nThe main questions the study aims to answer are:\n\nHow is the tolerability and the safety of One Strength up-dosing scheme in daily practice? This study includes approximately 105 patients (children (≥5 years), adolescents, and adults), receiving this treatment as part of their usual care.\n\nStudy data on safety and tolerability wil be collected for each patient during the first 8 injection visits.\n\nThe study will be conducted at 6-8 study sites in Poland.",[26,59,60,61,62],"Allergic Conjunctivitis Due to Dermatophagoides Farinae","Allergic Conjunctivitis Due to Dermatophagoides Pteronyssinus","Allergic Asthma Due to Dermatophagoides Farinae","Allergic Asthma Due to Dermatophagoides Pteronyssinus",[31,64,65,66,67,68,69,70,71,72,73],"Allergopharma","Novo-Helisen Depot","Allergy","House Dust Mites","One Strength","NHD (D.p.\u002FD.f.)","NHD","Children","poland","SCIT","NOT_YET_RECRUITING","2025-07-24",{"date":77,"type":38},"2025-07-31",{"date":79,"type":21},"2025-07-30",{"date":81,"type":21},"2026-06-30",{"name":83,"class":84},"Allergopharma GmbH & Co. KG","INDUSTRY",{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":96,"phases":97,"briefSummary":99,"conditions":100,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":4},"100478442","radiofrequency-ablation-of-bilateral-inferior-turbinate-followed-by-subcutaneous-immunotherapy-trial-100478442","NCT05510024","Radiofrequency Ablation of Bilateral Inferior Turbinate Followed by Subcutaneous Immunotherapy Trial","Radiofrequency Ablation of Bilateral Inferior Turbinate Followed by Subcutaneous Immunotherapy Trial for Severe House Dust Mite-sensitized Allergic Rhinitis","RABIT","Inclusion Criteria:\n\n* aged 18 to 60 years\n* at least 2-year history of physician-diagnosed HDM-AR, with positive skin prick test to house dust mite and\u002For positive serum antigen-specific IgE\n* nasal congestion score ≥7, severe inferior turbinate hypertrophy (no visible of middle turbinate)\n* no oral steroids for 4 weeks prior to treatment\n* no intranasal steroids and\u002For antihistamines for 2 weeks prior to recruitment\n\nExclusion Criteria:\n\n* symptomatic seasonal AR\n* any respiratory infection within the previous 4 weeks prior to recruitment\n* chronic rhinosinusitis with or without nasal polyps, nasal septum deviation, cleft lip and\u002For palate, autoimmune disorders, malignant tumor, immune deficiency disease, tuberculosis, cardiac dysfunction, uncontrolled asthma, beta blocker in taker, other severe systemic disease\n* pregnancy or breastfeeding females\n* those who had previously received AIT or nasal surgery within one month or those who participated other clinical trials within 3 months prior to recruitment","60 Years",{"count":95,"type":21},392,"INTERVENTIONAL",[98],"NA","Allergic rhinitis (AR) is a global health issue adversely impacting the quality of life (QoL) of affected individuals and exerting a huge public health burden. Allergen immunotherapy (AIT) has been shown to be effective in the treatment of not only the symptoms, but also the underlying causes of the disease. Moreover, AIT has a preventative role against new sensitizations and development of asthma in AR patients. Hence AIT is recommended as an integrated part of an allergy management strategy in the treatment of AR. Over the development of one century, AIT has been delivered by various routes. Among them, subcutaneous immunotherapy (SCIT) has been currently widely used in clinical practice.\n\nHouse dust mite (HDM) has been reported to be the most common sensitizing allergen in China. Nasal obstruction is the common complaint in HDM-sensitized AR and prompts patients to seek medical help. It has been proved that HDM-SCIT showed favourable efficacy in treating persistent AR. However, HDM-SCIT recommends 3 years of subcutaneous injection and requires good adherence to guarantee the efficacy. Later onset of nasal obstruction alleviation might reduce the adherence of HDM-SCIT.\n\nRadiofrequency ablation of bilateral inferior turbinate can relieve nasal obstruction within a short time after operation. It is hypothesized that, in HDM-AR patients with severe nasal obstruction, bilateral inferior turbinate surgery followed by HDM-SCIT will obtain quick-onset of good nasal ventilation and improve AIT adherence.\n\nThe overall objective of the proposed randomized controlled trial is to test whether radiofrequency ablation of bilateral inferior turbinate followed by subcutaneous immunotherapy will improve nasal obstruction among patients with house dust mite sensitized allergic rhinitis (HDM-AR) compared to subcutaneous immunotherapy (SCIT) only during the 4-month build-up phase as well as the 36-month full phase of SCIT.",[26],"2022-08-19",{"date":103,"type":38},"2022-08-22",{"date":105,"type":21},"2022-10-01",{"date":107,"type":21},"2026-12-31",{"name":109,"class":45},"Eye & ENT Hospital of Fudan University"]